Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

Lavanya Palavalli Parsons, MD
Published: Monday, Mar 26, 2018


Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.  

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x